Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly

Malaria Clinical Trial

— LiHMS  

Official title:

Prednisone Plus Chloroquine Versus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly in Papua New Guinea: a Randomized Open-label Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01785979
• Other study ID #: LiHMS
• Status: Withdrawn
• Phase: Phase 3
• First received: February 5, 2013
• Last updated: November 12, 2015
• Start date: January 2016
• Est. completion date: February 2017

Study information

• Verified date: November 2015
• Source: Lihir Medical Centre
• Contact: n/a
• Is FDA regulated: No
• Health authority: Papua New Guinea: Medical Society of Papua New Guinea
• Study type: Interventional

Clinical Trial Summary

This randomized clinical trial will address a complication related to recurrent episodes of malaria in endemic areas - hyper-reactive malarial splenomegaly. We aim to assess the efficacy of chloroquine after prednisone-induction therapy compared to standard treatment of chloroquine alone in the treatment of adult patients with newly diagnosed hyper-reactive malarial splenomegaly.

Description:

Hyper-reactive malarious splenomegaly (HMS) is a known chronic autoimmune complication in areas where malaria is endemic. Patients with HMS complain most commonly of abdominal swelling or pain from the enlarged spleen and the condition is defined using clear clinical and laboratory criteria. HMS appears benign in most patients when seen first but if untreated, it leads to severe anaemia and also acute bacterial infections. There is familiar and ethnic clustering suggesting genetic basis. High prevalence rates have been reported in certain areas of Papua New Guinea, and Venezuela, and HMS is also common in parts of sub-Saharan Africa, including Sudan and Ghana.

The treatment of HMS is still empirical since no randomized trials have been done so far. Long term anti-malarial chemoprophylaxis is deemed the mainstay of therapy, but the optimal drug-regimen and duration are unknown. Three to six months may pass before a response is observed, and relapses may occur when therapy is discontinued.

On the basis of the observed benefit in experimental studies, glucocorticoids have been used for severe hyper-reactive malarial splenomegaly in various case reports. Because these cases had a favourable outcome and the drug tolerability was good, prednisone has become an attractive therapeutic option for this disease. Central to the pathophysiology of HMS is the overproduction of Immunoglobulin M due to a functional CD8 T-cell defect and the consequent expansion and activation of B lymphocytes. Glucocorticoids may have an immediate effect due to inhibition of the sequestration of immunoglobulin coated red blood cells by the mononuclear phagocyte system and a later effect due to glucocorticoid-induced inhibition of antibody synthesis. We aim to assess the efficacy of chloroquine after prednisone-induction therapy compared to chloroquine alone in the treatment of adult patients with newly diagnosed hyper-reactive malarial splenomegaly.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Defining features of HMS including chronic massive splenomegaly (at least 10 cm below the costal margin); serum Immunoglobulin M elevated more than 3.1 g/L and high malarial antibody titres (above 640).

• Evidence of the polyclonal nature of the lymphocytes by serum immunoglobulin free light chains.

• Aged at least 18 years

• Haemoglobin level of > 5 mg/d

Exclusion Criteria:

• known allergy to chloroquine,

• use of anti-malarial treatment within the preceding month,

• suspected coexisting diseases in which glucocorticoids are contraindicated (e.g. diabetes mellitus, peptic ulcer disease or any acute infection as defined clinically), and

• splenomegaly secondary to known infectious or haematological causes

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anaemia
• Hyper-reactive Malarial Splenomegaly
• Malaria
• Splenomegaly

Intervention

Drug:
• prednisone induction - chloroquine
At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
• Chloroquine
At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.

Locations

Country	Name	City	State
Papua New Guinea	Lihir medical Centre	Londolovit	New ireland province

Sponsors (1)

Lead Sponsor	Collaborator
Lihir Medical Centre

Country where clinical trial is conducted

Papua New Guinea, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	composite clinical & immunological endpoint	Clinical cure, defined as a sustained reduction in spleen size of at least 40% at the 12 month follow up examination, compared with the spleen size at the baseline examination. Immunological cure, defined as a two-fold decrease of total immunoglobulin M levels is also needed.	12 months	No
Secondary	3 months intermediate clinical cure	Reduction in spleen size of at least 40% at the 3 month follow up examination	3 months	No
Secondary	6 months intermediate clinical cure	Reduction in spleen size of at least 40% at the 3 month follow up examination	6 months	No
Secondary	Anaemia	Incidence of HMS related-anemia defined by hemoglobin levels below 10 g/L at 12 months	12 months	No
Secondary	Malaria episode	occurrence of an acute episode of malaria identified by passive-case detection in the hospital facilities during the follow up period.	12 months	No
Secondary	Bacterial infection	occurrence of an acute bacterial infection identified by passive-case detection in the hospital facilities during the follow up period.	12 months	No